production of holmium-166 dotmp: a promising agent for bone marrow ablation in hematologic malignancies

نویسندگان

reza bagheri

amir reza jalilian

ali bahrami-samani

maohammad mazidi

mohammad ghannadi-maragheh

چکیده

intoduction: therapeutic radiopharmaceuticals are radiolabeled molecules to deliver sufficient doses of ionizing radiation to specific disease sites such as bone metastases, brain and liver tumors and bone marrows malignancies including multiple myeloma. among some therapeutic radiopharmaceuticals, 166ho-1,4,7,10 -tetraazacyclo dodecane-1,4,7,10 tetraethylene phosphonic acid (166ho-dotmp) is used for delivering high doses to bone marrow. in this research production, quality control, pharmacokinetics and biodistribution studies of 166ho-dotmp with respect to its radiochemical and in vivo biological characteristics have been presented. methods: holmium-166 was produced by irradiation of holmium oxide (ho2o3, purity > 99.8%) at a thermal neutron flux. 166ho-dotmp complex was obtained in very high yields (radiochemical purity > 99%) under the reaction conditions employed. radiochemical purity and the stability of the 166ho-dotmp complex in human serum were assayed. wild type rats were used for biodistribution and imaging studies of this agent. results: 166ho produced by irradiation of holmium-165 oxide demonstrated high radionuclide purity. 166ho-dotmp was obtained in very high yield (radiochemical purity > 99%) and the complex exhibited excellent in vitro stability at ph~7 when stored at room temperature and human serum. biodistribution studies in rats showed favorable selective skeletal uptake with rapid clearance from blood along with insignificant accumulation of activity in other non-target organs. the scintigraphic image recorded in rat at 3 h after the injection of the 166ho-dotmp radiopharmaceutical revealed that 166ho-dotmp rapidly accumulated in skeleton especially in the thigh bones. conclusion: biodistribution, stability, imaging and pharmacokinetics studies of  166ho-dotmp radiopharmaceutical in this research showed favorable features such as; rapid and selective skeletal  uptake, fast clearance from blood and almost no uptake in any other major organs. our research demonstrated that 166ho-dotmp has promising features suggesting good potential for efficient use of this radiopharmaceutical for bone marrow ablation in different hematologic malignancies including multiple myeloma.

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Production of Holmium-166 DOTMP: A promising agent for bone marrow ablation in hematologic malignancies

  Intoduction: Therapeutic radiopharmaceuticals are radiolabeled molecules to deliver sufficient doses of ionizing radiation to specific disease sites such as bone metastases, brain and liver tumors and bone marrows malignancies including multiple myeloma. Among some therapeutic radiopharmaceuticals, 166Ho-1,4,7,10 -tetraazacyclo dodecane-1,4,7,10 tetraethy...

متن کامل

Production of Holmium-166 DOTMP: A promising agent for bone marrow ablation in hematologic malignancies

Intoduction: Therapeutic radiopharmaceuticals are radiolabeled molecules to deliver sufficient doses of ionizing radiation to specific disease sites such as bone metastases, brain and liver tumors and bone marrows malignancies including multiple myeloma. Among some therapeutic radiopharmaceuticals, Ho-1,4,7,10 – tetraazacyclo dodecane–1,4,7,10 tetraethylene phosphonic acid (Ho-DOTMP) is used fo...

متن کامل

Bone marrow transplantation in dogs after radio-ablation with a new Ho-166 amino phosphonic acid bone-seeking agent (DOTMP).

beta-emitting 166Ho (t1/2 = 26.78 hours, E(beta)max = 1.8 MeV) complexed with the phosphonic acid chelator, 1,4,7,10 tetraazacyclododecane-1,4,7,10-tetra(methylene phosphonic acid) (DOTMP) at a ligand-to-metal ratio of 1.5:1 binds to bone. This radioactive complex is a marrow-ablating radiopharmaceutical that appears useful for preparation of bone marrow (BM) transplant recipients without the m...

متن کامل

Mixed hematopoietic chimerism following bone marrow transplantation for hematologic malignancies.

Twenty-nine of 172 patients (17%) who received an allogeneic bone marrow transplant (BMT) from histocompatible sibling donors for hematologic malignancies were mixed hematopoietic chimeras; ie, they had a mixture of donor and host hematopoietic or lymphohematopoietic cells at greater than or equal to 14 days after transplantation. Twenty-four of the 29 mixed chimeras (83%) have remained in cont...

متن کامل

Magnetic resonance imaging of the bone marrow in hematologic malignancies.

Magnetic resonance imaging (MRI) offers a global view of the bone marrow and facilitates the understanding of disease progression and the remission of hematologic malignancies. Marrow MRI is an important tool for accurate diagnosis, monitoring of disease extent, and evaluation of treatment response. MRI functions as an adjunct to bone marrow aspiration and biopsy. Furthermore, abnormal imaging ...

متن کامل

Development of 166Ho-zoledronate as a bone marrow ablative agent

In this study, production, quality control and biodistribution studies of 166Ho-zoledronate have been presented as a possible bone marrow ablative agent. Ho-166 chloride was produced by thermal neutron irradiation of natural 165Ho(NO3)3 samples. 166Ho-zoledronate complex was prepared by adding the desired amount of zoledronate solution (0.2 mL, 150 mg/ml in 1 M NaOH) to appropriate amount of th...

متن کامل

منابع من

با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید


عنوان ژورنال:
iranian journal of nuclear medicine

ناشر: tehran university of medical sciences

ISSN 1681-2824

دوره 19

شماره 1 2011

میزبانی شده توسط پلتفرم ابری doprax.com

copyright © 2015-2023